Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

Ho Young Yhim; Na Ri Lee; Eun Kee Song; Chang Yeol Yim; So Yeon Jeon; Seunghwan Shin; Jeong A. Kim; Hee Sun Kim; Eun Hae Cho; Jae Yong Kwak

doi:10.1016/j.leukres.2012.02.011

Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

Ho Young Yhim, Na Ri Lee, Eun Kee Song, Chang Yeol Yim, So Yeon Jeon, Seunghwan Shin, Jeong A. Kim, Hee Sun Kim, Eun Hae Cho, Jae Yong Kwak

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Abstract

The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5. months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%. All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted.

Original language	English
Pages (from-to)	689-693
Number of pages	5
Journal	Leukemia Research
Volume	36
Issue number	6
DOIs	https://doi.org/10.1016/j.leukres.2012.02.011
State	Published - Jun 2012

Bibliographical note

Funding Information:
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea ( 0620220–1 ).

Keywords

Chronic myeloid leukemia
Complete molecular response
Imatinib mesylate
Real-time quantitative polymerase chain reaction

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2012.02.011

Cite this

Yhim, H. Y., Lee, N. R., Song, E. K., Yim, C. Y., Jeon, S. Y., Shin, S., Kim, J. A., Kim, H. S., Cho, E. H., & Kwak, J. Y. (2012). Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leukemia Research, 36(6), 689-693. https://doi.org/10.1016/j.leukres.2012.02.011

@article{41879f189860498d932772bae9db932e,

title = "Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response",

abstract = "The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5. months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%. All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted.",

keywords = "Chronic myeloid leukemia, Complete molecular response, Imatinib mesylate, Real-time quantitative polymerase chain reaction",

author = "Yhim, {Ho Young} and Lee, {Na Ri} and Song, {Eun Kee} and Yim, {Chang Yeol} and Jeon, {So Yeon} and Seunghwan Shin and Kim, {Jeong A.} and Kim, {Hee Sun} and Cho, {Eun Hae} and Kwak, {Jae Yong}",

note = "Funding Information: This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea ( 0620220–1 ). ",

year = "2012",

month = jun,

doi = "10.1016/j.leukres.2012.02.011",

language = "English",

volume = "36",

pages = "689--693",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

AU - Yhim, Ho Young

AU - Lee, Na Ri

AU - Song, Eun Kee

AU - Yim, Chang Yeol

AU - Jeon, So Yeon

AU - Shin, Seunghwan

AU - Kim, Jeong A.

AU - Kim, Hee Sun

AU - Cho, Eun Hae

AU - Kwak, Jae Yong

N1 - Funding Information: This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea ( 0620220–1 ).

PY - 2012/6

Y1 - 2012/6

N2 - The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5. months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%. All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted.

AB - The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5. months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%. All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted.

KW - Chronic myeloid leukemia

KW - Complete molecular response

KW - Imatinib mesylate

KW - Real-time quantitative polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=84862794931&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.02.011

DO - 10.1016/j.leukres.2012.02.011

M3 - Article

C2 - 22398220

AN - SCOPUS:84862794931

SN - 0145-2126

VL - 36

SP - 689

EP - 693

JO - Leukemia Research

JF - Leukemia Research

IS - 6

ER -

Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this